• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Toward personalized, targeted therapy of gastrointestinal stromal tumor.

作者信息

Trent Jonathan C

机构信息

Department of Sarcoma Medical Oncology, Sarcoma Research Center, The University of Texas, M. D. Anderson Cancer Center, Houston, TX.

出版信息

Gastrointest Cancer Res. 2008 Sep;2(5):256-7.

PMID:19259311
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2632559/
Abstract
摘要

相似文献

1
Toward personalized, targeted therapy of gastrointestinal stromal tumor.迈向胃肠道间质瘤的个性化靶向治疗。
Gastrointest Cancer Res. 2008 Sep;2(5):256-7.
2
FDG-PET to Measure Response to Targeted Therapy: The Example of Gastrointestinal Stromal Tumor and Imatinib Mesylate (Gleevec).用氟代脱氧葡萄糖正电子发射断层扫描（FDG-PET）评估靶向治疗的疗效：以胃肠道间质瘤和甲磺酸伊马替尼（格列卫）为例
PET Clin. 2008 Jan;3(1):77-87. doi: 10.1016/j.cpet.2008.08.001. Epub 2008 Nov 27.
3
Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.临床相关性的药物遗传学在胃肠道间质瘤治疗在个性化治疗时代。
Pharmacogenomics. 2013 Jun;14(8):941-56. doi: 10.2217/pgs.13.63.
4
[Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].[野生型胃肠道间质瘤的特征与靶向治疗]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Sep 25;23(9):907-910. doi: 10.3760/cma.j.cn.441530-20200614-00356.
5
Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?琥珀酸脱氢酶缺陷型胃肠道间质瘤：迈向个性化医疗的小步伐？
Epigenet Insights. 2019 Apr 12;12:2516865719842534. doi: 10.1177/2516865719842534. eCollection 2019.
6
New developments in gastrointestinal stromal tumor.胃肠道间质瘤的新进展
Curr Opin Oncol. 2006 Jul;18(4):386-95. doi: 10.1097/01.cco.0000228747.02660.e2.
7
Predictors of response to targeted therapies for gastrointestinal stromal tumors.胃肠道间质瘤靶向治疗反应的预测因素。
Arch Pathol Lab Med. 2012 May;136(5):483-9. doi: 10.5858/arpa.2011-0082-RA. Epub 2012 Jan 9.
8
[Significance of circulating tumor cell monitoring in targeted therapy for gastrointestinal stromal tumors].[循环肿瘤细胞监测在胃肠道间质瘤靶向治疗中的意义]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Sep 25;24(9):789-795. doi: 10.3760/cma.j.cn.441530-20201209-00655.
9
Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies.胃肠道间质瘤的靶向治疗与个性化医疗：耐药性、机制及治疗策略
Onco Targets Ther. 2019 Jul 1;12:5123-5133. doi: 10.2147/OTT.S180763. eCollection 2019.
10
Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.蛋白质组学在肉瘤个体化治疗中的应用：从胃肠道间质瘤预后生物标志物发现中得到的启示。
Proteomics Clin Appl. 2013 Jan;7(1-2):70-8. doi: 10.1002/prca.201200085.

引用本文的文献

1
Immunotherapy and Targeted Therapies in Sarcoma: Proposed Synergy with Combination Treatment.肉瘤的免疫疗法和靶向疗法：联合治疗的潜在协同作用
J Immunother Precis Oncol. 2025 Aug 25;8(3):212-221. doi: 10.36401/JIPO-25-10. eCollection 2025 Aug.

本文引用的文献

1
Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.不吉利的数字13？KIT基因第13外显子突变在胃肠道间质瘤中的不同效应。
Mol Oncol. 2008 Aug;2(2):161-3. doi: 10.1016/j.molonc.2008.05.002. Epub 2008 May 10.
2
Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors.优化甲磺酸伊马替尼在胃肠道间质瘤中的治疗
Gastrointest Cancer Res. 2008 Sep;2(5):245-50.
3
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.无伊马替尼血浆水平与目标基因型与疗效和耐受性的关系。
Br J Cancer. 2008 May 20;98(10):1633-40. doi: 10.1038/sj.bjc.6604355. Epub 2008 May 6.
4
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.III期随机组间试验，评估甲磺酸伊马替尼在两个剂量水平对表达kit受体酪氨酸激酶的不可切除或转移性胃肠道间质瘤患者的疗效：S0033。
J Clin Oncol. 2008 Feb 1;26(4):626-32. doi: 10.1200/JCO.2007.13.4452.
5
Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.甲磺酸伊马替尼治疗的胃肠道间质瘤患者瘤内血管内皮生长因子表达与临床结局的相关性
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6727-34. doi: 10.1158/1078-0432.CCR-07-0895.
6
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.晚期胃肠道间质瘤患者的KIT突变与伊马替尼剂量选择
Eur J Cancer. 2006 May;42(8):1093-103. doi: 10.1016/j.ejca.2006.01.030. Epub 2006 Apr 18.
7
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.高剂量伊马替尼治疗胃肠道间质瘤的无进展生存期：随机试验
Lancet. 2004;364(9440):1127-34. doi: 10.1016/S0140-6736(04)17098-0.
8
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.在欧洲癌症研究与治疗组织（EORTC）软组织和骨肉瘤小组的I期和II期研究中，使用c-KIT/PDGFRA突变分析来预测晚期胃肠道间质瘤患者对伊马替尼的临床反应。
Eur J Cancer. 2004 Mar;40(5):689-95. doi: 10.1016/j.ejca.2003.11.025.
9
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.KIT突变类型、有丝分裂活性和组织学亚型在胃肠道间质瘤中的预后价值。
J Clin Oncol. 2002 Sep 15;20(18):3898-905. doi: 10.1200/JCO.2002.03.095.